IMNM Stock Up 32% after 5-Day Win Streak
Immunome (IMNM) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 32% return. The company has gained about $279 Mil in value over the last 5 days, with its current market capitalization at about $879 Mil. The stock remains 4.2% above its value at the end of 2024. This compares with year-to-date returns of 7.3% for the S&P 500.
Comparing IMNM Stock Returns With The S&P 500
The following table summarizes the return for IMNM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | IMNM | S&P 500 |
|---|---|---|
| 1D | 2.3% | 0.1% |
| 5D (Current Streak) | 31.8% | 1.1% |
| 1M (21D) | 26.5% | 5.7% |
| 3M (63D) | 38.4% | 22.3% |
| YTD 2025 | 4.2% | 7.3% |
| 2024 | -0.7% | 23.3% |
| 2023 | 384.2% | 24.2% |
| 2022 | -82.9% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 90 S&P constituents with 3 days or more of consecutive gains and 18 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 25 | 15 |
| 4D | 15 | 2 |
| 5D | 45 | 1 |
| 6D | 0 | 0 |
| 7D or more | 5 | 0 |
| Total >=3 D | 90 | 18 |
Key Financials for Immunome (IMNM)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $14.0 Mil | $9.0 Mil |
| Operating Income | $-28.7 Mil | $-153.5 Mil |
| Net Income | $-106.8 Mil | $-293.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $2.7 Mil | $2.9 Mil |
| Operating Income | $-55.6 Mil | $-44.6 Mil |
| Net Income | $-80.2 Mil | $-41.6 Mil |
While IMNM stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.